Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy01:26

Imaging Studies III: Gastrointestinal Motility Studies and Virtual Colonoscopy

49
This lesson explores three gastrointestinal imaging techniques: radionuclide testing, colonic transit studies, and virtual colonoscopy.
Radionuclide Testing
Radionuclide testing is a sophisticated medical technique for assessing gastrointestinal motility. It focuses on gastric emptying and colonic transit time. Radioactive markers track the movement of food through the digestive system, providing insights into gastrointestinal disorders.
In gastric emptying studies, a meal's liquid and...
49
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

271
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
271
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Antibiotic Effects of Investigational Drugs on Commensal Bacteria with Machine Learning.

ACS pharmacology & translational science·2026
Same author

High-throughput identification of bacterial β-glucuronidase inhibitors using machine learning.

Gut microbes·2026
Same author

Microbubbles manufactured using a tissue homogeniser: DoE-guided optimisation for a narrower size distribution and higher yield.

International journal of pharmaceutics·2026
Same author

Artificial intelligence-enabled personalisation of oral drug delivery: From data-driven design to on-demand manufacturing.

Advanced drug delivery reviews·2026
Same author

A multi-strain probiotic modulates gut microbiome composition, intestinal barrier integrity and inflammation in a multi-compartmental in vitro gut model of decompensated advanced chronic liver disease.

International journal of pharmaceutics·2026
Same author

Technical pen-based printhead for high-precision microdosing of personalized therapies.

Drug delivery and translational research·2026

Related Experiment Video

Updated: Jun 5, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Advances in colon-targeted drug technologies.

Charlotte Yeung1, Laura E McCoubrey1,2, Abdul W Basit1

  • 1University College London, School of Pharmacy, London.

Current Opinion in Gastroenterology
|December 5, 2024
PubMed
Summary

Innovative oral drug delivery systems are advancing colon-targeted therapies for inflammatory bowel disease (IBD). Novel technologies ensure consistent drug release, overcoming physiological variability for better treatment outcomes.

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.2K

Related Experiment Videos

Last Updated: Jun 5, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.0K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.2K

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Biomedical Engineering

Background:

  • The colon's unique physiological conditions (pH, microbiota) are leveraged for targeted drug delivery.
  • Variability in gastrointestinal physiology poses challenges for consistent colonic drug release.
  • Inflammatory Bowel Disease (IBD) treatment can benefit from advanced colonic drug delivery systems.

Purpose of the Study:

  • To review innovative oral technologies for colonic drug delivery.
  • To highlight advancements in treating IBD with these systems.
  • To discuss the translational and clinical progress of these technologies.

Main Methods:

  • Review of recent breakthroughs in colonic drug delivery systems.
  • Analysis of technologies incorporating multiple independent trigger mechanisms.
  • Exploration of 3D printing for personalized medicine in colonic delivery.

Main Results:

  • New systems with multiple triggers enhance drug release reliability despite physiological variability.
  • Advanced platforms are crucial for developing oral biologics, particularly for IBD.
  • 3D printing offers potential for personalized colonic drug delivery.

Conclusions:

  • Novel colonic drug delivery technologies enable accurate therapeutic targeting beyond the GI tract.
  • Focus on clinical translatability and scalability is essential for realizing the full potential of these systems.
  • These advancements hold promise for improved IBD management and other colonic-targeted treatments.